Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
Date:2/21/2008

NEW YORK, Feb. 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Monday, February 25, 2008 at 8:30 a.m. EST to discuss the fourth quarter and year-end 2007 financial results and business outlook for 2008. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-877-874-1565 (U.S.), 1-719-325-4750 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide) oral gelcaps, previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end- stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

CONTACT: Lauren Fischer, Director - Investor Relations of Keryx Biopharmaceuticals, Inc., +1-212-531-5965, lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
10. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/29/2019)... (PRWEB) , ... October 29, 2019 , ... ... signature of the skin*. Using Silios CMS-C multispectral imagers , researchers identified ... approach can replace identification based on retinal imaging, face recognition, fingerprints and vasculature. ...
(Date:10/22/2019)... ... October 22, 2019 , ... DermBiont, ... its lead program, DBI-001, met its primary safety endpoints, with no application site ... clinical trial for the treatment of interdigital tinea pedis (athlete’s foot). Additionally, the ...
(Date:10/10/2019)... (PRWEB) , ... October 09, 2019 , ... ... 10th, groups of Montgomery County middle school and high school students have improved ... stressors, utilize relaxation techniques and physical fitness, and apply lifelong social/interpersonal, leadership, problem-solving ...
(Date:10/8/2019)... ... October 08, 2019 , ... Today, Massachusetts stem cell ... lead development technology. Like the company’s precursor patent, approved in the U.S. in ... of tissue stem cells. Asymmetrex now markets the technology in the U.S. as ...
Breaking Biology Technology:
(Date:11/5/2019)... ... November 05, 2019 , ... Catalent, the leading global ... therapies, and consumer health products, today announced it will present at the upcoming ... Nov. 12 – 14, 2019. , On Wednesday, Nov. 13 at 3:20 p.m., ...
(Date:11/2/2019)... ... ... In this podcast, Smith spoke about the history of his career and how ... the Lab Podcast is an interview series initiated by Vanderbilt University School of Medicine’s ... field — and in these interviews, the alumni discuss the different facets, challenges and ...
(Date:10/30/2019)... ... 29, 2019 , ... LGC Maine Standards releases VALIDATE® UC1 ... 701sa & 704sa. The kits, in a human-urine matrix, evaluate CA, CL, CREA, ... kit, liquid, ready-to-use, and prepared using the CLSI EP06-A “equal delta” sample preparation, ...
Breaking Biology News(10 mins):